T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens, thereby engaging with CD3 on the T cell receptor. This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells. These antibodies have emerged as one of the most promising avenues within tumor immunotherapy. However, despite success in treating hematological malignancies, significant advancements in solid tumors have yet to be explored. In this review, we aim to address the critical challenges associated with T cell-redirecting bispecific antibodies and explore novel strategies to overcome these obstacles, with the ultimate goal of expanding the application of this therapy to include solid tumors.

中文翻译：

---

向前迈进：T细胞重定向双特异性抗体在癌症治疗中的应用

T 细胞重定向双特异性抗体经过专门设计，可与肿瘤相关抗原结合，从而与 T 细胞受体上的 CD3 结合。肿瘤细胞和 T 细胞之间的这种联系主动触发 T 细胞激活并启动对已识别肿瘤细胞的靶向杀伤。这些抗体已成为肿瘤免疫治疗中最有前途的途径之一。然而，尽管在治疗血液恶性肿瘤方面取得了成功，但实体瘤的重大进展仍有待探索。在这篇综述中，我们的目标是解决与 T 细胞重定向双特异性抗体相关的关键挑战，并探索克服这些障碍的新策略，最终目标是将这种疗法的应用范围扩大到包括实体瘤。